Incyte

from Wikipedia, the free encyclopedia
Incyte Corporation
legal form Corporation
ISIN US45337C1027
founding 2001
Seat Wilmington , Delaware
management Hervé Hoppenot
(President and CEO, 2014)
sales $ 1.5 billion (2017)
Branch Pharmaceutical company
Website www.incyte.com

Incyte Inc. is a US pharmaceutical company based in Wilmington , Delaware . The company markets the US Food and Drug Administration (FDA) -approved drug Jakafi ( trademark ) containing the active ingredient ruxolitinib , which has been prescribed to thousands of patients in the United States.

In 2014, the company appointed Hervé Hoppenot as President and CEO. Hoppenot was previously President of Novartis' Oncology Department and had been with the company since 2003.

Web links

Individual evidence

  1. ↑ Annual report. Incyte, accessed April 6, 2018 .
  2. ^ A b Cori Anne Natoli: Incyte looks to ride on drug's success. The News Journal, May 5, 2012, accessed May 6, 2014 .
  3. ↑ a b People . In: Gen. Closely. Biotechnol. News , February 15, 2014, p. 41.